In the complex with an A2AR antagonist, TM-V can instead contribute to stabilizing the high affinity state conformation of the D2R binding site, leading to the increased dopaminergic D2R signaling sought in treatment of Parkinson’s disease (Fuxe et al., 2007b; Armentero et al., 2011). The gene discussed is DRD2; the disease is Parkinson disease.